Skip to main content
SUTRO BIOPHARMA, INC. logo

SUTRO BIOPHARMA, INC. — Investor Relations & Filings

Ticker · STRO ISIN · US8693671021 LEI · 5493005U6P15VD25P851 US Manufacturing
Open in API
Filings indexed 585 across all filing types
Latest filing 2022-06-09 Director's Dealing
Country US United States of America
Listing US STRO

About SUTRO BIOPHARMA, INC.

https://www.sutrobio.com/

Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of precisely designed cancer therapeutics. The company leverages its proprietary, integrated cell-free protein synthesis platform to create novel antibody-drug conjugates (ADCs). This technology enables the development of next-generation ADCs, including those with single and dual payloads, which are designed to offer improved therapeutic profiles for patients with cancer. Sutro is advancing its own pipeline of clinical-stage product candidates to address areas of significant unmet medical need.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2022-06-09 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 6, 2022, by Sutro Biopharma, Inc. The key content is the submission of matters to a vote of security holders at the 2022 Annual Meeting of Stockholders. It details the election of directors, ratification of the independent auditor, and advisory votes on executive compensation. This matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA), which includes official results from shareholder votes at any general meeting. The document is not a full annual report, audit report, or management report, but specifically reports voting outcomes. The length is under 5,000 characters, but it contains substantive voting results, not just an announcement of a report publication. Therefore, the correct classification is DVA with high confidence.
2022-06-07 English
Regulatory Filings 2022
Regulatory Filings
2022-05-20 English
POS EX
Regulatory Filings Classification · 100% confidence The document is a Post-Effective Amendment No. 3 to a Form S-3 Registration Statement filed with the SEC by Sutro Biopharma, Inc. It updates the auditors' consent and includes exhibits related to underwriting agreements, bylaws, certificates, and consents. The document is a regulatory filing related to securities registration and amendments, not a financial report, earnings release, or other specific report type. It is a formal SEC filing updating registration information and consents, fitting the category of Regulatory Filings (RNS).
2022-05-18 English
10-Q
Interim / Quarterly Report Q1 2022
2022-05-09 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 9, 2022, by Sutro Biopharma, Inc. It announces the issuance of a press release regarding financial results for the quarter ended March 31, 2022. The text explicitly states that the press release is attached as Exhibit 99.1 and that the information is being furnished and not filed, indicating this document is an announcement rather than the full earnings release itself. The document length is 3651 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this is a Regulatory Filing (RNS) type, as it does not contain the full financial results but only announces their release and attaches the press release as an exhibit.
2022-05-09 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.